MX2022013230A - Analogos de glucagon como agonistas de accion prolongada del receptor de glp-1/glucagon para usarse en el tratamiento de enfermedad del higado graso y esteatohepatitis. - Google Patents
Analogos de glucagon como agonistas de accion prolongada del receptor de glp-1/glucagon para usarse en el tratamiento de enfermedad del higado graso y esteatohepatitis.Info
- Publication number
- MX2022013230A MX2022013230A MX2022013230A MX2022013230A MX2022013230A MX 2022013230 A MX2022013230 A MX 2022013230A MX 2022013230 A MX2022013230 A MX 2022013230A MX 2022013230 A MX2022013230 A MX 2022013230A MX 2022013230 A MX2022013230 A MX 2022013230A
- Authority
- MX
- Mexico
- Prior art keywords
- glucagon
- liver disease
- fatty liver
- treatment
- steatohepatitis
- Prior art date
Links
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 title abstract 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 2
- 208000004930 Fatty Liver Diseases 0.000 title 1
- 108010063919 Glucagon Receptors Proteins 0.000 title 1
- 102100040890 Glucagon receptor Human genes 0.000 title 1
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 title 1
- 208000010706 fatty liver disease Diseases 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 7
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 229940123232 Glucagon receptor agonist Drugs 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 102100040918 Pro-glucagon Human genes 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere al uso médico de análogos de glucagón de acción prolongada específicos que tienen actividad agonista dual del receptor de GLP-1/glucagón en la prevención y/o el tratamiento de la enfermedad hepática metabólica, en particular, la enfermedad del hígado graso no alcohólico (NAFLD), hígado graso no alcohólico (NAFL), esteatohepatitis no alcohólica (NASH), fibrosis hepática y/o cirrosis asociadas a NAFLD.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20171285 | 2020-04-24 | ||
| PCT/EP2021/060532 WO2021214220A1 (en) | 2020-04-24 | 2021-04-22 | Glucagon analogues as long-acting glp-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013230A true MX2022013230A (es) | 2022-11-14 |
Family
ID=70464848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013230A MX2022013230A (es) | 2020-04-24 | 2021-04-22 | Analogos de glucagon como agonistas de accion prolongada del receptor de glp-1/glucagon para usarse en el tratamiento de enfermedad del higado graso y esteatohepatitis. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11813312B2 (es) |
| EP (1) | EP4138874A1 (es) |
| JP (1) | JP2023522364A (es) |
| KR (1) | KR20230005289A (es) |
| CN (1) | CN115484972A (es) |
| AU (1) | AU2021259336A1 (es) |
| BR (1) | BR112022019618A2 (es) |
| CA (1) | CA3176613A1 (es) |
| CL (1) | CL2022002818A1 (es) |
| MX (1) | MX2022013230A (es) |
| TW (1) | TW202206450A (es) |
| WO (1) | WO2021214220A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021214019A1 (en) | 2020-04-24 | 2021-10-28 | Bayer Aktiengesellschaft | Substituted aminothiazoles as dgkzeta inhibitors for immune activation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| TWI674270B (zh) | 2012-12-11 | 2019-10-11 | 英商梅迪繆思有限公司 | 用於治療肥胖之升糖素與glp-1共促效劑 |
| CN105745222A (zh) * | 2013-10-17 | 2016-07-06 | 西兰制药公司 | 酰化胰高血糖素类似物 |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| SG11201806342SA (en) | 2016-03-10 | 2018-08-30 | Medimmune Ltd | Glucagon and glp-1 co-agonists for the treatment of obesity |
| TW201832783A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物 |
| AU2018314773A1 (en) * | 2017-08-09 | 2020-03-26 | Sanofi | GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis |
| US20200268835A1 (en) | 2019-02-27 | 2020-08-27 | Novo Nordisk A/S | Compounds For Use in NASH |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
-
2021
- 2021-04-22 EP EP21719664.1A patent/EP4138874A1/en active Pending
- 2021-04-22 KR KR1020227041173A patent/KR20230005289A/ko active Search and Examination
- 2021-04-22 BR BR112022019618A patent/BR112022019618A2/pt unknown
- 2021-04-22 WO PCT/EP2021/060532 patent/WO2021214220A1/en unknown
- 2021-04-22 US US17/237,210 patent/US11813312B2/en active Active
- 2021-04-22 MX MX2022013230A patent/MX2022013230A/es unknown
- 2021-04-22 AU AU2021259336A patent/AU2021259336A1/en active Pending
- 2021-04-22 CA CA3176613A patent/CA3176613A1/en active Pending
- 2021-04-22 CN CN202180030561.4A patent/CN115484972A/zh active Pending
- 2021-04-22 JP JP2022563880A patent/JP2023522364A/ja active Pending
- 2021-04-23 TW TW110114641A patent/TW202206450A/zh unknown
-
2022
- 2022-10-13 CL CL2022002818A patent/CL2022002818A1/es unknown
-
2023
- 2023-09-28 US US18/476,587 patent/US20240123037A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021259336A1 (en) | 2022-10-20 |
| TW202206450A (zh) | 2022-02-16 |
| JP2023522364A (ja) | 2023-05-30 |
| BR112022019618A2 (pt) | 2022-11-16 |
| CL2022002818A1 (es) | 2023-06-16 |
| CN115484972A (zh) | 2022-12-16 |
| KR20230005289A (ko) | 2023-01-09 |
| US20210330749A1 (en) | 2021-10-28 |
| US11813312B2 (en) | 2023-11-14 |
| EP4138874A1 (en) | 2023-03-01 |
| US20240123037A1 (en) | 2024-04-18 |
| WO2021214220A1 (en) | 2021-10-28 |
| CA3176613A1 (en) | 2021-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500761A1 (en) | Co-agonists of glucagon and glp-1 receptors | |
| PH12020551025A1 (en) | Incretin analogs and uses thereof | |
| MY195618A (en) | Use of a Long Acting Glp-1/Glucagon Receptor Dual Agonist for the Treatment of Non-Alcoholic Fatty Liver Disease | |
| PH12020551024A1 (en) | Incretin analogs and uses thereof | |
| MX2018005193A (es) | Proteinas de doble funcion y composicion farmaceutica que comprende las mismas. | |
| MA46219B1 (fr) | Composés de co-agonistes du glucagon et du glp-1 | |
| MY156316A (en) | Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products | |
| MX2018005194A (es) | Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas. | |
| NZ746784A (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| MX2010004388A (es) | Formulaciones de hormona paratiroidea y usos de las mismas. | |
| MX2022004146A (es) | Composición farmacéutica de vector de virus adenoasociado y métodos. | |
| PH12019501528A1 (en) | Combination therapy for nonalcoholic steatohepatitis (nash) and liver fibrosis | |
| MX2022013230A (es) | Analogos de glucagon como agonistas de accion prolongada del receptor de glp-1/glucagon para usarse en el tratamiento de enfermedad del higado graso y esteatohepatitis. | |
| RU2020109881A (ru) | Агонисты рецепторов glp-1/глюкагона в лечении жировой болезни печени и стеатогепатита | |
| MX2017004614A (es) | Preparacion compuesta, que contiene derivado novedoso de acido 3-(4-(benciloxi)fenil)hex-4-inoico y otro ingrediente activo, para prevenir o tratar enfermedades metabolicas. | |
| EA202091464A1 (ru) | Композиции для лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита | |
| MX2021002655A (es) | Terapia de combinacion para el tratamiento de enfermedad hepatica. | |
| MX2022007666A (es) | Analogos de incretina y sus usos. | |
| MX2022007929A (es) | Coagonistas de triazol grapados de los receptores de glucagon y glp-1. | |
| MX2022000388A (es) | Terapia de combinacion de agonista de gpr119 e inhibidores de dpp-4. | |
| MX2022007926A (es) | Coagonistas lactamicos grapados de los receptores de glucagon y glp-1. | |
| MX2022007928A (es) | Co-agonistas de olefina engrapados de los receptores de glucagon y glp-1. | |
| EA201890714A1 (ru) | Композиция для лечения бесплодия у субъекта женского пола | |
| TH1701002228A (th) | อะโกนิสต์ร่วมของกลูคากอนและ glp-1 รีเซปเตอร์ |